The Impact of Biosimilars on Pharmaceutical Marketing and Commercial Strategy in Global Biologics Markets

Biosimilars were introduced into regulated markets as a cost containment mechanism modelled loosely on small molecule generics. This paper argues that their more consequential effect has been structural rather than fiscal: Biosimilars have dismantled the marketing logic on which the branded biologics industry was built. Drawing on market data, regulatory documents and corporate disclosures published during 2023 and 2024, and situating these against a conceptual literature on regulated market positioning, health system financing, supply chain governance and commercial data infrastructure, the study examines how biosimilar competition reallocated commercial power from prescribers to intermediaries, forced originators into portfolio substitution rather than brand defence, and produced a new channel form, the payer affiliated private label biosimilar, that has no clear precedent in pharmaceutical distribution.

Four findings are advanced. First, the decisive commercial variable in 2024 was not clinical differentiation or regulatory status but formulary architecture: The removal of Humira from a major national commercial formulary in April 2024 moved more market share in weeks than the preceding period of biosimilar promotion had moved. Second, interchangeability, long treated by manufacturers as a commercial asset worth substantial clinical investment, was empirically decoupled from market share and then regulatorily devalued by the FDA's June 2024 draft guidance. Third, originators increasingly responded to loss of exclusivity not by defending the eroding asset but by migrating demand to adjacent, patent protected molecules, a strategy visible in AbbVie's transfer of immunology revenue from Humira to Skyrizi and Rinvoq. Fourth, the pharmacy benefit and medical benefit now behave as two distinct markets requiring incompatible commercial models.

The paper further argues that the capabilities determining biosimilar commercial outcomes are increasingly infrastructural rather than promotional, residing in contracting systems, customer data architecture, analytics governance, distribution visibility and manufacturing quality assurance. It concludes that biosimilar marketing has become an exercise in channel economics and gross to net engineering rather than in demand generation, and that this shift carries consequences for market sustainability, patient access and the durability of biosimilar development pipelines.